Story perspectives

Bristol Myers Squibb Commits $40 Billion to U.S. Innovation

5/8/2025

25 5

Summary

Story summary

Bristol Myers Squibb (BMS) will invest $40 billion in U.S. R&D, technology, and manufacturing over five years, emphasizing radiopharmaceuticals and AI.
CEO Chris Boerner urged for supportive tax policies and criticized potential pharmaceutical tariffs that could hinder innovation.
BMS is cutting 516 jobs in New Jersey as part of cost-cutting measures due to expiring drug patents.
Other pharmaceutical companies, like Johnson & Johnson and Eli Lilly, are also committing to substantial U.S. manufacturing investments.

1 of 1

Story summary

Bristol Myers Squibb (BMS) will invest $40 billion in U.S. R&D, technology, and manufacturing over five years, emphasizing radiopharmaceuticals and AI.
CEO Chris Boerner urged for supportive tax policies and criticized potential pharmaceutical tariffs that could hinder innovation.
BMS is cutting 516 jobs in New Jersey as part of cost-cutting measures due to expiring drug patents.
Other pharmaceutical companies, like Johnson & Johnson and Eli Lilly, are also committing to substantial U.S. manufacturing investments.